← Issue №14/ week of Oct 4, 2026/Hepatology

Short-course prophylaxis with the Toronto HCV protocol for recipients of non-liver solid organ transplants from donors with hepatitis C viraemia: a retrospective, matched cohort study.

From GI Signals issue №14: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology retrospective · n=116 · Sep 29, 2026 · Lancet GH · IF 39.1

Short-course prophylaxis with the Toronto HCV protocol for recipients of non-liver solid organ transplants from donors with hepatitis C viraemia: a retrospective, matched cohort study.

New evidenceviral hepatitisliver transplant
Clinical takeawayConsider adopting the Toronto HCV protocol (glecaprevir 300 mg/day, pibrentasvir 120 mg/day, and ezetimibe 10 mg/day for 8 days) for HCV-negative recipients of non-liver solid organ transplants from HCV NAT-positive donors, acknowledging the retrospective design and monitoring for adverse events.
What it foundThe Toronto HCV protocol achieved undetectable HCV RNA at 12 weeks post-transplantation in 100% of recipients (n=116) of non-liver solid organ transplants from HCV NAT-positive donors, compared to the standard 8-12 week course.
ContextThis study confirms the efficacy of a short-course (8-day) antiviral protocol in HCV-negative recipients of non-liver solid organ transplants from HCV NAT-positive donors, challenging the standard 8-12 week course, and supports its adoption as a new standard of care, though further prospective studies are needed.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Aleyadeh W … Feld JJ · Lancet Gastroenterology & Hepatology · IF 39.1 · PubMed ↗Permalink
← Read the whole of issue №14 Every paper GI Signals surfaces gets a page like this one. All issues